Viridian Therapeutics (VRDN) Prices Upsized 10.67M Share Offering at $18.75/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
September 11, 2024 11:25 PM EDTWALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering price of $18.75 per share and 20,000 shares of Series B non-voting convertible preferred stock at a public offering price of $1,250.06250 per share, which... More



